Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
Triple meeting 2025 – Zai discloses pivotal DLL3 plans
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
Zelgen’s DLL3 trispecific goes pivotal
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
DLL3 goes trispecific
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
ESMO 2023 – tarlatamab hits the target for Amgen
But late-breaking data raise questions about lack of a dose response.
